Evidence map›Paper›PMID 36895027›Full record

ArticleCell & bioscience2023

GPR116 receptor regulates the antitumor function of NK cells via Gαq/HIF1α/NF-κB signaling pathway as a potential immune checkpoint.

Dandan Guo, Chenxu Jin, Yaoxin Gao, Haizhen Lin, Li Zhang, Ying Zhou, Jie Yao, Yixin Duan, Yaojun Ren, Xinhui Hui and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Dandan Guo *Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Chenxu Jin *Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Yaoxin GaoShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Haizhen LinShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Li ZhangShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Ying ZhouShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Jie YaoShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Yixin DuanShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Yaojun RenShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Xinhui HuiShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Yujia GeShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Renzheng YangShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China.
Wenzheng JiangShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, 500 Dongchuan Rood, Shanghai, 200241, China. wzjiang@bio.ecnu.edu.cn.ORCID http://orcid.org/0000-0003-4999-4168
East China Normal University · CN

Funding

National Key Research and Development Program of China 2021YFF0702400National Natural Science Foundation of China 81072459National Natural Science Foundation of China 81771306Science and Technology Commission of Shanghai Municipality 201409002900Science and Technology Commission of Shanghai Municipality 21S11906200
6 · The paper itself

Abstract

backgroundNK cell is one of innate immune cells and can protect the body from cancer-initiating cells. It has been reported that GPR116 receptor is involved in inflammation and tumors. However, the effect of GPR116 receptor on the NK cells remains largely unclear.

resultsWe discovered that GPR116

conclusionsOur data indicated that GPR116 receptor had a negatively effect on NK cell function and downregulation of GPR116 receptor in NKG2D-CAR-NK92 cells could enhance the antitumor activity, which provides a new idea to enhance the antitumor efficiency of CAR NK cell therapy.

Indexed as

GPR116HIF1αImmunotherapyNKNK-κB

Identifiers

PMID36895027
PMCPMC9999509
OpenAlexW4323660448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.